V
Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
SIX:VIFN
Price:
166.15 CHF
0.48%
Market Closed
Updated:
May 3, 2024
Vifor Pharma AG
Net Income (Common)
|
Vifor Pharma AG
Net Income (Common) Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
V
|
Vifor Pharma AG
SIX:VIFN
|
Net Income (Common)
CHf144.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
|
|
Novartis AG
SIX:NOVN
|
Net Income (Common)
$14.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Net Income (Common)
-$16.5m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Net Income (Common)
CHf11.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Net Income (Common)
$848m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Net Income (Common)?
Net Income (Common)
144.4m
CHF
144.4m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Net Income (Common) amounts to 144.4m CHF.
What is Vifor Pharma AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-4%
-4%
Over the last year, the Net Income (Common) growth was -60%. The average annual Net Income (Common) growth rates for Vifor Pharma AG have been -2% over the past three years , -9% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
